Practice Areas

• Antidepressant Birth Defects
• Car Accidents
• 18 Wheeler Accidents
• Motorcycle Accidents
• ATV-Watercraft Accident
• Day Care Accident
• Wrongful Death Cases
• Work Injury
• Construction Accident Lawyer
• Oil Rig Accidents & Explosions
• Welding Accidents & Deaths
• Fire & Explosion Accidents
• Chemical Exposure
• Mesothelioma Attorneys
• Yaz-Yasmin Drug Reaction
• Darvon & Darvocet
• Bankruptcy
• Chapter 13 Bankruptcy
• Chapter 7 Bankruptcy
• Foreclosure
• Reposession
• Bancarrota
• Consumer Privacy Law
• Class Action Lawsuits
• Transvaginal Mesh Injuries
• Accidentes de Auto
• Accidente de 18 Wheeler
• Motociclismo Accidente

Our Blogs

• Texas Bankruptcy Law Blog
• Texas Injury Law Blog

Avandia Reaction, We Can Help File Your Lawsuit

Avandia Lawyers

If you have taken Avandia and suffered serious side effects—you are not alone.  Avandia has been linked to thousands of heart attacks, strokes, and congestive heart failure by the United States Food & Drug Administration (FDA). Avandia has been allowed to remain on the market—putting countless lives at risk. If you or a loved one has taken Avandia and suffered a heart attack, stroke or congestive heart failure, our Avandia lawyers want to hear from you today.

A Senate Finance Committee report released in February 2010 found that GlaxoSmithKline, the maker of Avandia, not only knew about this drug's heart attack risks as early as 1999, but worked to keep vital safety information from the public. Our Avandia lawyers are determined to make sure the drug company is held accountable for its failure to warn patients about Avandia's serious health risks—heart attack, stroke and congestive heart failure.

If you or a loved one suffered a heart attack, stroke, or congestive heart failure while taking Avandia, you may be eligible to receive compensation for your medical bills, lost wages, and pain and suffering. Please call one of our experienced Avandia lawyers today to protect your legal rights.

Senate Finance Committee Report – Avandia

Avandia (rosiglitazone) is manufactured by GlaxoSmithKline, and is a thiazolidinedione agent, a class of drugs approved by the FDA in 1998 to treat type 2 diabetes by helping control blood sugar levels. At its peak in 2006, 13.2 million people had taken Avandia. But by 2008, concerns over side effects had caused that number to fall to 4.6 million.

Avandia’s cardiovascular problems have been the subject of concern since May 2007, when an analysis of 42 clinical trials published by the Cleveland Clinic showed that patients taking the drug had a 43-percent higher risk of having a heart attack. In November 2007, a black box warning–the FDA’s strongest safety warning–detailing Avandia’s association with myocardial ischemia was added to the drug’s labeling.

The Senate Finance Committee Avandia report released in February 2010 was the result of a 2-year investigation and draws from more than 250,000 pages of documents provided by GlaxoSmithKline, the FDA and several research institutes, as well as interviews with officials from both the company and agency, and anonymous whistleblowers. According to the Senate report, the FDA's own reviewers recommended that Avandia be removed from the market as early as 2007.

The report maintains that 500 heart attacks and 300 cases of heart failure could be avoided each month if diabetics taking Avandia were treated with an alternative medication. In July 2007 the FDA’s own scientists estimated that Avandia was responsible for an estimated 83,000 heart attacks, the Senate report says. The report maintains that some of those could have been avoided if Glaxo had considered Avandia’s cardiovascular risks in 1999 when they were first raised. Instead, the report maintains that Glaxo tried to undermine criticism of the drug:

“GSK executives attempted to intimidate independent physicians, focused on strategies to minimize or misrepresent findings that Avandia may increase cardiovascular risk and sought ways to downplay findings that a competing drug might reduce cardiovascular risk,” the report says.

The Senate committee report doesn’t address whether Avandia should be taken off the market, but documents included with it indicate that some FDA reviewers clearly thought that should happen. For instance, an October 2008 internal FDA memo authored by Dr. David Graham and Dr. Kate Gelperin recommended then that Avandia be removed from the market because of heart risks, but nothing was done. Dr. Graham had actually argued to an advisory panel in 2007 that Avandia sales should be stopped. Unfortunately, that panel voted 22-1 to recommend Avandia remain on the market.

According to the Senate report, FDA reviewers also questioned an Avandia study called TIDE being conducted by GlaxoSmithKline. TIDE, which will compare Avandia with another diabetes treatment, Actos, was ordered by the FDA in 2007, when it mandated the black box heart attack warning. Reviewers called the study “unethical and exploitative” because patients given Avandia face far greater risks than those given Actos, with no promise of any additional benefit. Despite these concerns, TIDE was still enrolling patients as of February 2010.

At the same time they released the Senate report, Sens. Max Baucus (D., Mont.), chairman of the Finance Committee and Chuck Grassley (R., Iowa), the panel’s leading Republican, wrote to the FDA asking it to take more stringent actions to protect the public from Avandia health risks, and expressing concern that the TIDE trial was allowed to proceed.

“Americans have a right to know there are serious health risks associated with Avandia and GlaxoSmithKline had a responsibility to tell them. Patients trust drug companies with their health and their lives and GlaxoSmithKline abused that trust,” Sen. Baucus said in a statement announcing the Senate Finance Committee's Avandia findings. “We will continue watching closely and working with the FDA to make sure patients and doctors are aware of the risks associated with Avandia and all drugs so they can make safe and informed decisions when choosing their medicines.”

Avandia Lawsuit for Heart Attack, Stroke, and Congestive Heart Failure

The Senate Finance Committee Avandia report paints a damning profile of both GlaxoSmithKline and the FDA. Had either put the interests of patients first, thousands of Avandia-related heart attacks may have been prevented. Filing an Avandia heart attack lawsuit is one way victims of this drug can make sure GlaxoSmithKline is held accountable for the way it handled Avandia's heart risks.

If you or someone you love suffered a heart attack, stroke or congestive heart failure while taking Avandia, you have legal rights. Please fill out our online form or call (866) 705-7584 as soon as possible to discuss your case with one of our Avandia injury lawyers.

4925 Greenville Ave Suite 715, Dallas, TX 75206 (214) 890-0711
Avandia Google Reviews  | Avandia Death Google Reviews | Texas Personal Injury Blog | Texas Bankruptcy Blog